✨Happy holidays and best wishes for 2026 from Thermal!✨

The biggest scientific breakthroughs of the last 25 years—and a few to watch From decoding the human genome to exploring the universe, science has made huge strides in the 21st century.

National Geographic names CRISPR among the biggest scientific breakthroughs of the last 25 years and gives @jenniferdoudna.bsky.social @innovativegenomics.bsky.social the last word on what's next.
www.nationalgeographic.com/science/arti...

Reflections on Proteomics - 2025 Year-End Wrap-Up Parag and Andreas share their reflection on proteomics in 2025.

In this 2025 wrap‑up episode of the #TranslatingProteomics podcast, Parag Mallick and Andreas Huhmer share their reflections on the year’s developments in proteomics largely inspired by their observations at HUPO 2025.

www.nautilus.bio/blog/reflect...

The Rarest of All Diseases Are Becoming Treatable This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

.@jenniferdoudna.bsky.social and @urnov.bsky.social at the @innovativegenomics.bsky.social in @theatlantic.com on how a platform approach to CRISPR could finally change the economics of treating rare diseases and why Baby KJ’s treatment is the proof of concept.
www.theatlantic.com/science/2025...

Nautilus at HUPO 2025 - Redefining proteomics with single-molecule Iterative Mapping Find our takeaways from HUPO 2025 and learn why we're excited work with members of the HUPO community to redefine proteomics!

The rapid pace of innovation reflects the ingenuity and creativity of researchers in the field. For our takeaways from HUPO 2025, check out this blog:

www.nautilus.bio/blog/nautilu...

Can genetic medicine solve cardiovascular disease? Scribe Therapeutics CEO on how CRISPR technologies are ready to move beyond rare diseases and take on the world’s biggest killers.

We’re excited to be featured in @longevitytech.bsky.social, where @mrdannysullivan.bsky.social sits down with our CEO @benjaminloakes.bsky.social to discuss how next-gen CRISPR therapies could extend lifespans by revolutionizing the treatment paradigm for CVD.

Read the full piece: bit.ly/4riTDZn

Listen to Scribe’s co-founder, Jennifer Doudna, speak to the vision that Scribe was founded on – unlocking #CRISPR to revolutionize the standard of care for cardiometabolic disease.

"I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵

We're excited to share breakthrough preclinical data across our cardiometabolic pipeline presented at #AHA25, highlighting our comprehensive strategy to address the key drivers of #ASCVD.

Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...

UC Berkeley’s Omar Yaghi shares 2025 Nobel Prize in Chemistry - Berkeley News Yaghi created a field called reticular chemistry, which involves stitching together molecular building blocks to form porous structures — metal-organic frameworks (MOFs) — with myriad applications.

1/2 From IGI Founder @jenniferdoudna.bsky.social: “Congratulations to my colleagues Omar Yaghi & John Clarke — the two latest UC Berkeley Nobel Laureates! Omar’s development of metal-organic frameworks changed the way we capture carbon, store energy & harvest water from desert air. shorturl.at/GpBsu

Portrait of Jane Goodall

From IGI Founder Jennifer Doudna: "Jane Goodall showed us what a life in science could look like: rigorous discovery paired with fierce advocacy for what you study. She gave the world six decades of groundbreaking research on chimpanzees and their habitats... 1/2

Ahead of #WorldHeartDay, Taylor Swift recently raised an important reminder: heart disease is the leading cause of death, and one person dies from it every 34 seconds.

For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.

Treating High Cholesterol Could Become A One-And-Done Treatment Gene editing and epigenetic silencing offer two ways of changing the basic biology of cholesterol for future treatments beyond statins.

An important piece in @forbes.com by Leaps By Bayer highlighting the dangers of high cholesterol, the urgent need for solutions beyond statins, and Scribe’s advances developing #CRISPR gene editing and epigenetic silencing therapies for cardiometabolic disease.

www.forbes.com/sites/juerge...

ON CRISPR Episode 1: Beginnings Podcast Episode · ON CRISPR: The Story of Jennifer Doudna with Walter Isaacson · S3 E1 · 26m

Check out ON CRISPR: The Story of Jennifer Doudna - a new podcast from Walter Isaacson about the story of @jenniferdoudna.bsky.social - CRISPR co-inventor, Nobel laureate, @innovativegenomics.bsky.social founder - and key updates, including the case of Baby KJ. podcasts.apple.com/us/podcast/o...

📣 Presenting new breakthrough data from two of our core platforms 📣

We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics.

More details in our link below 👇

The Billionaires Fueling the Quest for Longer Life A network of ultrawealthy investors including Peter Thiel and Sam Altman are infusing the longevity industry with cash and making big bets on where the science is headed.

Thanks to Amy Marcus, Alex Janin, and Shane Shifflett @wsj.com for covering the $5B longevity investment landscape, including our clients BioAge and Retro, and the ecosystem of companies working to translate aging research into therapies for longer, healthier lives.
www.wsj.com/health/welln...

This fall, we are thrilled to present our latest updates on our #CRISPR genetic and epigenetic editing therapies, new machine learning approach, and corporate strategy at several premier conferences.

If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇

Exclusive: OpenAI, Retro Bio detail lab results with AI protein model, plan use in drug program OpenAI and Retro Biosciences report AI-made proteins showed 50x better cell reprogramming using modified Yamanaka factors, with potential therapeutic applications

Exclusive: I talked with leaders of OpenAI and Retro Bio about new lab results from an AI protein model called GPT-4b micro.

While the model won't be released publicly, the research shows how LLMs could be applied to life sciences research:
endpoints.news/openai-retro...

Exclusive: Formation licenses first drug since $372M raise, eyes more deals in 2025 Formation Bio licenses first-in-class anti-CD226 antibody from IMIDomics for IBD treatment, marking first drug acquisition since $372M Series D raise in 2023.

Exclusive: Formation Bio raised a $372M Series D last year.

Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.

My latest for @endpts.com: endpoints.news/exclusive-fo...

CRISPR pioneer and Nobel laureate @jenniferdoudna.bsky.social is featured in the inaugural issue of The Shift. This first issue honors Gloria Steinem's legacy and brings together 90 extraordinary women whose work is opening doors for future generations. theshiftison.com/jennifer-dou...

CRISPR researchers and startup entrepreneurs will share new building in UC Berkeley's Innovation Zone - Berkeley News A planned addition to the campus's Innovation Zone will expand lab space for the Innovative Genomics Institute and build out the largest innovation hub — Bakar Labs — at any U.S. university.

We’re thrilled to announce IGI–Bakar Labs. This new building will allow the IGI to continue expanding our impact in health and agricultural applications of #CRISPR, and will be shared with the Bakar Labs incubator for growing biotech companies. Learn more: news.berkeley.edu/2025/07/17/c...

Our conversation photo and photo of Baby KKJ

A new Pediatric Center for CRISPR Cures builds on the recent saved life of Baby KJ, who expeditiously had bespoke in vivo base genome editing
@jenniferdoudna.bsky.social @doudna-lab.bsky.social
@innovativegenomics.bsky.social
@chanzuckerberg.bsky.social
erictopol.substack.com/p/new-center...

Aysel Ogul, an undergraduate research assistant at the IGI, pipetting in the lab with her mentor Kevin Briseno

We're excited to announce that the IGI is teaming up with @chanzuckerberg.bsky.social to create a new center for pediatric #CRISPR cures @UCSF + @ucberkeleyofficial.bsky.social building on the recent success of an on-demand CRISPR therapy for Baby KJ. Read more: ow.ly/XUQH50Wmt7U

Iterative Mapping of proteoforms may reveal novel biology and new drug targets Learn how Iterative Mapping of proteoforms can provide novel insights into biology with tau proteoforms as exemplars.

On the blog, we’re diving into data from our new preprint covering Iterative Mapping of proteoforms. Today we focus on the method, its benefits, and why the analysis of tau proteoforms is a great exemplar for the power of this work:

www.nautilus.bio/blog/iterati...

#Proteomics #Proteoforms

Agenus and Noetik Collaboration Will Predict Cancer Biomarkers Using the Virtual Cell Noetik will use its multimodal AI models to identify which patients will most likely benefit from Agenus’s lead immuno-oncology combination, BOT/BAL.

Read @faylinphd.bsky.social’s article for more context. www.genengnews.com/topics/artif...

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Agenus and Noetik announced a collaboration to develop AI-enabled predictive biomarkers for BOT/BAL using foundation models of “virtual cell” biology. www.businesswire.com/news/home/20...

I witnessed the birth of an immortality cult — surely it can’t last? The tech bros believe we are close to conquering death. Matt Rudd travels to the ‘superhuman summit’ in Stockholm to sample body scanners and bone broth

Joe Betts-LaCroix (CEO of Retro Bio) has bigger concerns - he wants to add another ten years to the lifespan of half the world’s population.

“I’d like to know how my body works and, if it’s going to break, I’d like to know how to prevent that.”
www.thetimes.com/world/europe...

The Hidden Barriers Holding Back Promising Cancer Treatments A perfect storm of scientific, economic, and cultural barriers are holding back immunotherapy's true potential, writes Samir Khleif.

“The Hidden Barriers Holding Back Cancer’s Most Promising Treatments” by Georgiamune CEO Samir N. Khleif for TIME.
time.com/7292783/canc...

Genesis Therapeutics Appoints Aleksandra Faust as Chief Artificial Intelligence Officer Genesis Therapeutics appoints Aleksandra Faust as Chief Artificial Intelligence Officer

Genesis Therapeutics Appoints Aleksandra Faust
as Chief Artificial Intelligence Officer.

Former Google DeepMind Director brings over two decades of AI research expertise and industrial leadership to Genesis’ AI platform and high-performing research teams.
www.businesswire.com/news/home/20...

Baby KJ looking alert and healthy

Thanks to the BBC's The Inquiry program for great conversations with IGI's @jenniferdoudna.bsky.social @doudna-lab.bsky.social and @urnov.bsky.social about Baby KJ, #CRISPR on-demand, and the future of personalized medicine!

Listen here: www.bbc.com/audio/play/w...

Photo credit: TODAY

🧬CRISPR is moving at breakneck speed! Join @jenniferdoudna.bsky.social and @emilychang.bsky.social on 6/5 for a live episode of #TheCircuit at #BloombergTech. From curing baby KJ to AIxCRISPR, this will be a candid conversation on gene editing's impact and future.
Livestream: www.bloomberg.com/live